SensoDetect presents new strategy and launches new product in 2018

The new board and the team of SensoDetect have the last 4 months worked in a focused manner to detail the long-term strategy of the company as well as securing the funds and resources to realize the same. Thanks to this work and the strong evidence presented in the research from Uppsala University Hospital, “Auditory brainstem response (ABR) profiling tests as diagnostic support for schizophrenia and adult attention-deficit hyperactivity disorder (ADHD)”, on our technology, we are now in a state where we can share our Vision, Mission, Strategy and Targets with shareholders and potential new investors.